• Tue, November 15, 2022

Mark Breidenbach Maintained (SYRS) at Buy with Decreased Target to $15 on, Nov 15th, 2022

Mark Breidenbach of Oppenheimer, Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Buy with Decreased Target from $30 to $15 on, Nov 15th, 2022.

Mark, nor any peers, have made any analyst calls on SYRS in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Like: 👍